Top pharmaceutical company evaluates Optimer for precision liver medicine

  • 📰 NewsMedical
  • ⏱ Reading Time:
  • 40 sec. here
  • 10 min. at publisher
  • 📊 Quality Score:
  • News: 47%
  • Publisher: 71%

Liver Noticias

Medicine,Aptamer,Cell

Optimer delivery vehicle has been shipped to a pharma partner for external evaluation.

From Aptamer GroupApr 22 2024Reviewed by Lily Ramsey, LLM Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces that its Optimer binder against cells associated with fibrotic liver disease, developed for targeted delivery of therapeutic payloads to fibrotic liver disease, has been shipped to a top 15 pharmaceutical company for evaluation in their own therapeutic applications.

This allows the gene therapy to be effective in target fibrotic liver disease cells, with no effect in the non-target liver cells. A significant effect was seen from the Optimer-delivered gene therapy, compared to the gene therapy alone, with a p-value of less than 0.01, indicating the probability of these results is more than 99% due to the Optimer delivery of the gene therapy.

Targeted delivery to specific cell populations is showing increasing use across the pharmaceutical sector, as it holds the potential for increased efficacy and reduced side effects from medications. Exemplar publicised partnerships for specifically targeted precision medicine developments include Ionis Pharmaceuticals Inc. licensing a single delivery vehicle from Bicycle Therapeutics Inc.

 

Gracias por tu comentario. Tu comentario será publicado después de ser revisado.
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

 /  🏆 19. in MX

México Últimas Noticias, México Titulares